138 completed, 62 recruiting, 43 active not recruiting, 41 terminated. 196 Phase 2, 125 Phase 1, 28 Phase 3, 9 Not applicable, 8 Early Phase 1.
Follow Mantle Cell Lymphoma: new trials by email Literature Review of Mantle Cell Lymphoma trials Research Report on Mantle Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma Zanubrutinib, Obinutuzumab, Sonrotoclax - Mantle Cell Lymphoma | Phase 2 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 45 | 2026-09-01 | 2026-09-10 |
| Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Allogeneic NK cells, Rituximab, Tafasitamab - Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma | Phase 1 | Recruiting | Paolo Caimi, MD | 15 | 2026-09-01 | 2026-09-09 |
| Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy Zanubrutinib, Sonrotoclax, CAR-T Cell Therapy - Mantle Cell Lymphoma | Phase 2 | Recruiting | Canadian Cancer Trials Group | 40 | 2026-08-24 | 2026-10-14 |
| Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy Atrial Fibrillation (AF), Chronic Lymphocytic Leukemia | Not yet recruiting | Tina Baykaner | 500 | 2026-08-01 | 2026-07-17 | |
| HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell Lymphoma Phase Ib Cohort 1: HDM2005 1.2 mg/kg + R-Len, Rituximab plus lenalidomide, Phase Ib Cohort 2: HDM2005 1.4 mg/kg + R-Len - Mantle Cell Lymphoma | Phase 1 | Not yet recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 40 | 2026-07-10 | 2026-07-13 |
| Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors Connected home blood pressure monitoring with daily IPA supervision. - Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma ( FL) | Not applicable | Not yet recruiting | Centre Hospitalier de la côte Basque | 40 | 2026-07-01 | 2026-06-22 |
| Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy Glofitamab - Mantle Cell Lymphoma | Phase 2 | Recruiting | Fondazione Italiana Linfomi - ETS | 41 | 2026-06-05 | 2026-06-25 |
| A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma Rocbrutinib, Ibrutinib, Acalabrutinib - Mantle Cell Lymphoma | Phase 3 | Recruiting | Guangzhou Lupeng Pharmaceutical Company LTD. | 394 | 2026-02-05 | 2026-02-06 |
| PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma Pirtobrutinib - Mantle Cell Lymphoma | Phase 2 | Not yet recruiting | Fondazione Italiana Linfomi - ETS | 56 | 2026-02-01 | 2025-10-06 |
| Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma Zanubrutinib, Obinutuzumab, Lenalidomide - Mantle Cell Lymphoma | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 37 | 2025-12-20 | 2026-05-13 |
| The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas Cancer Therapeutic Procedure, Questionnaire Administration - Amyloidosis, Basal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 27 | 2025-12-18 | 2026-09-30 |
| Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas Pemigatinib - Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma | Phase 2 | Active not recruiting | University of Utah | 1 | 2025-10-03 | 2026-07-09 |
| Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment Bendamustine + anti-CD20 monoclonal antibody/orelabrutinib + anti-CD20 monoclonal antibody - Mantle Cell Lymphoma | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 45 | 2025-10-01 | 2025-10-03 |
| Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 30 | 2025-06-02 | 2026-04-22 |
| Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101 - B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Vironexis Biotherapeutics Inc. | 32 | 2025-05-30 | 2026-10-26 |
| Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Mantle Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | OHSU Knight Cancer Institute | 27 | 2025-05-29 | 2026-01-30 |
| BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma Bendamustine, Rituximab, Cytarabine - Mantle Cell Lymphoma, Lymphoma | Phase 2 | Recruiting | Christine Ryan | 60 | 2025-04-22 | 2026-02-20 |
| Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment Non-Interventional Study - Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma | Recruiting | OHSU Knight Cancer Institute | 45 | 2025-03-10 | 2026-09-23 | |
| A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) Sonrotoclax, Zanubrutinib, Placebo - Mantle Cell Lymphoma, B Cell Lymphoma | Phase 3 | Recruiting | BeOne Medicines | 300 | 2025-03-05 | 2026-09-28 |
| LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies Pirtobrutinib, LV20.19 CAR T cells - Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | Phase 1 | Recruiting | Medical College of Wisconsin | 12 | 2025-02-06 | 2026-08-06 |
Showing 20 of 339. Sign in to see all of them.
Lymphoma, Mantle-Cell (339) · Lymphoma, Follicular (107) · Leukemia, Lymphocytic, Chronic, B-Cell (96) · Lymphoma, Large B-Cell, Diffuse (96) · Lymphoma, B-Cell, Marginal Zone (75) · Lymphoma, Non-Hodgkin (75) · Lymphoma (52) · Lymphoma, B-Cell (37) · Waldenstrom Macroglobulinemia (36) · Burkitt Lymphoma (30) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (27) · Multiple Myeloma (25) · Recurrence (23) · Hodgkin Disease (21) · Leukemia, Myeloid, Acute (17)
Hemic and Lymphatic Diseases (339) · Immune System Diseases (338) · Lymphatic Diseases (338) · Neoplasms by Histologic Type (338) · Immunoproliferative Disorders (337) · Lymphoproliferative Disorders (334) · Neoplasms (330) · Lymphoma (287) · Lymphoma, Non-Hodgkin (264) · Hematologic Diseases (123) · Pathologic Processes (119) · Pathological Conditions, Signs and Symptoms (119) · Disease Attributes (115) · Lymphoma, B-Cell (109) · Leukemia, Lymphoid (107)
Rituximab (84) · ibrutinib (35) · Bendamustine Hydrochloride (33) · Cyclophosphamide (32) · Lenalidomide (30) · Bortezomib (26) · Cytarabine (24) · fludarabine (23) · obinutuzumab (21) · acalabrutinib (18) · venetoclax (18) · zanubrutinib (17) · CT-P10 (15) · Vincristine (14) · Doxorubicin (13)
M.D. Anderson Cancer Center (19) · Fondazione Italiana Linfomi - ETS (9) · Fred Hutchinson Cancer Center (9) · Memorial Sloan Kettering Cancer Center (9) · City of Hope Medical Center (7) · Weill Medical College of Cornell University (6) · BeOne Medicines (5) · Emory University (5) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (5) · Gilead Sciences (4) · H. Lee Moffitt Cancer Center and Research Institute (4) · Janssen Research & Development, LLC (4) · Mayo Clinic (4) · Millennium Pharmaceuticals, Inc. (4) · National Cancer Institute (NCI) (4)
United States (221) · China (48) · France (31) · Italy (29) · United Kingdom (29) · Spain (26) · Germany (25) · Australia (21) · Canada (21) · Poland (17) · South Korea (16) · Belgium (12) · Brazil (11) · Israel (11) · Sweden (10)
Anita Kumar, MD (3) · Brenda Sandmaier (3) · Alexey V Danilov (2) · Andre Goy, MD (2) · Brad S Kahl, M.D. (2) · Brad S Kahl, MD (2) · Christine Ryan, MD (2) · Douglas Gladstone, MD (2)
PMID 34398557, PMID 34515338, PMID 17242396, PMID 32126141, PMID 32499241, PMID 34780125, PMID 34797699, PMID 36485104, PMID 38669626, PMID 12620412, PMID 12907446, PMID 16116429, PMID 16123218, PMID 16766582, PMID 17299095, PMID 19238148, PMID 20220059, PMID 20626754, PMID 20956803, PMID 21816833, PMID 22058200, PMID 23782157, PMID 23782682, PMID 23834234, PMID 23940282, PMID 24019544, PMID 24048792, PMID 24591201, PMID 24652994, PMID 24919854, PMID 25016003, PMID 25145344, PMID 25361987, PMID 25381051, PMID 25696919, PMID 25738670, PMID 25921098, PMID 26059948, PMID 26096944, PMID 26205583, PMID 26535512, PMID 26640039, PMID 26659572, PMID 26673811, PMID 26729345, PMID 26738796, PMID 26755518, PMID 26875824, PMID 26968534, PMID 27354719
P30CA015704 (6), P30CA033572 (5), 2015 (3), 2018 (3), P30CA015083 (3), P30CA016672 (3), P30CA138292 (3), 2005 (2), 2014 (2), P01CA018029 (2), P01CA078902 (2), R35CA197353 (2), U10CA180820 (2), 2009 (1), 2016 (1)